Back to mobile site

Nymox Pharma (NYMX) Announces Successful, Long-Term Fexapotide Phase 3 Data in Prostate Cancer

August 24, 2016 12:25 PM EDT Send to a Friend
Nymox Pharmaceutical Corporation (Nasdaq: NYMX) announces successful new study results from the long-term blinded placebo crossover group from the U.S ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login